In patients with AF and chronic coronary artery disease (beyond one year after revascularization or coronary artery disease not requiring coronary revascularization) without a history of stent thrombosis, oral anticoagulant monotherapy is recommended over the combination therapy of oral anticoagulant and single antiplatelet agent (aspirin or P2Y12 inhibitor) to decrease the risk of major bleeding [31]. Here, P2RY12 is linked to atrial fibrillation.